BioMed Research International / 2009 / Article / Fig 6

Research Article

Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy

Figure 6

Time schedules and results for tumor volumes, survival periods, and rates for treatment with Protocol number 4. (a) Protocols of Groups I, II, III, and IV. (b) Tumor volumes on day 14 after re-challenge with B16F1 cells. All data are presented as mean ± standard deviation. Tumor volumes of Groups I and III on day 14 were significantly reduced compared with that of the control group ( and , resp.) by Scheffé test. (c) Kaplan-Meier survival curve over a period of 60 days after re-challenge. Survival rates of Group I and III were significantly prolonged compared with that of the control group ( 4 and , resp.). Four of the eight mice in Group I and three of the seven mice in Group III were protected against re-challenge with B16F1 melanoma cells. (d) Tumor volumes of the primary tumor and re-challenge tumor as representative examples of Groups I ( ) and IV ( ) which were treated at C for 15 minutes and C for 30 minutes, respectively. All data are presented as mean ± standard deviation.
457936.fig.006a
(a)
457936.fig.006b
(b)
457936.fig.006c
(c)
457936.fig.006d
(d)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.